secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2026-06-02T11:05:59+00:00
Accession:  0001104659-26-069206
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute reports positive interim Phase 3 upLIFT data: 6 of 8 patients met primary endpoint
--------------------------------------------------------------------------------

- 8 patients enrolled (50% of planned 16); 6 responders with ≥50% reduction in IV glucose, all 6 achieved complete discontinuation.
- One patient withdrew due to cancer progression (Stage 4 colon cancer) counted as non-responder; one patient recently enrolled and dosing.
- No drug-related adverse events; all completing pivotal phase entered open-label extension, cumulative treatment up to 6 months.
- Topline results for fully enrolled study expected in second half of 2026.
- Data supports ersodetug as potential universal treatment for refractory hypoglycemia from congenital and acquired hyperinsulinism.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465926069206/0001104659-26-069206-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465926069206/tm2616579d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-069206

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer